uniQure (NASDAQ:QURE) Stock Rating Upgraded by Cantor Fitzgerald

uniQure (NASDAQ:QURE) was upgraded by Cantor Fitzgerald to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

Other equities research analysts have also recently issued research reports about the stock. Guggenheim reissued a “buy” rating and issued a $28.00 target price on shares of uniQure in a research report on Monday, May 12th. HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of uniQure in a research report on Monday, April 21st. Wells Fargo & Company dropped their price target on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a research report on Friday, February 28th. StockNews.com upgraded uniQure to a “sell” rating in a research note on Tuesday, March 11th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $24.00 price objective on shares of uniQure in a research note on Tuesday, January 21st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $37.82.

uniQure Stock Up 4.1%

Shares of QURE opened at $15.31 on Monday. The firm has a market cap of $838.62 million, a P/E ratio of -3.09 and a beta of 0.10. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18. The firm’s 50-day simple moving average is $12.37 and its 200 day simple moving average is $12.45.

uniQure (NASDAQ:QURE) last announced its earnings results on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.25. The company had revenue of $1.57 million for the quarter, compared to analyst estimates of $5.93 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. On average, analysts forecast that uniQure will post -3.75 earnings per share for the current year.

Insider Activity at uniQure

In other news, CFO Christian Klemt sold 14,341 shares of the business’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total transaction of $153,448.70. Following the sale, the chief financial officer now directly owns 152,372 shares in the company, valued at approximately $1,630,380.40. The trade was a 8.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Matthew C. Kapusta sold 6,717 shares of uniQure stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total transaction of $76,036.44. Following the sale, the chief executive officer now owns 580,795 shares in the company, valued at approximately $6,574,599.40. This represents a 1.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 90,830 shares of company stock valued at $961,401. 4.74% of the stock is owned by insiders.

Institutional Trading of uniQure

Institutional investors and hedge funds have recently bought and sold shares of the stock. Twin Tree Management LP acquired a new position in uniQure during the 4th quarter worth about $77,000. ADAR1 Capital Management LLC acquired a new position in shares of uniQure in the fourth quarter worth approximately $177,000. Mraz Amerine & Associates Inc. bought a new stake in uniQure in the first quarter valued at approximately $106,000. China Universal Asset Management Co. Ltd. boosted its holdings in uniQure by 9.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock valued at $195,000 after acquiring an additional 969 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in uniQure by 13.9% during the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock valued at $217,000 after purchasing an additional 1,503 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.